| Original language | English (US) |
|---|---|
| Pages (from-to) | 1176-1184 |
| Number of pages | 9 |
| Journal | American Journal of Psychiatry |
| Volume | 175 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2018 |
ASJC Scopus subject areas
- Psychiatry and Mental health
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American Journal of Psychiatry, Vol. 175, No. 12, 12.2018, p. 1176-1184.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - When discontinuing SSRI antidepressants is a challenge
T2 - Management tips
AU - Jha, Manish K
AU - Rush, A. John
AU - Trivedi, Madhukar H
N1 - Funding Information: From the Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas; Duke–National University of Singapore, Singapore; the Department of Psychiatry, Duke University Medical School, Durham, N.C.; and Texas Tech Health Sciences Center–Permian Basin, Midland-Odessa. Address correspondence to Dr. Trivedi (madhukar.trivedi@utsouthwestern. edu). Supported through the Center for Depression Research and Clinical Care (principal investigator, Dr. Trivedi) and the Hersh Foundation. The authors thank Jeremy Kee, M.A., and Taryn Mayes, M.S., for administrative support. Dr. Jha has received contract research funding from Acadia Pharmaceuticals and Janssen Research. Dr. Rush has received consulting fees from Akili, Brain Resource, Compass, Curbstone Consultant, Eli Lilly, the Emmes Corporation, Johnson & Johnson (Janssen), LivaNova, MindLinc, Sunovion, Takeda USA, and Taj Medical; he has received speaking fees from LivaNova and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas (for the Inventory of Depressive Symptoms and its derivatives); and he is named co-inventor on two patents (7,795,033 and 7,906,283, on methods to predict outcome and risk of side effects with antidepressant treatment). Dr. Trivedi has served as a consultant or on advisory boards for Alkermes, Akili Interactive, Allergan Pharmaceuticals, Acadia Pharmaceuticals, Avanir Pharmaceuticals, Brintellix Global, Bristol-Myers Squibb, Caudex, Cerecor, Forest Pharmaceuticals, Global Medical Education, Health Research Associates, Insys, Johnson & Johnson Pharmaceutical Research and Development, Lilly Research Laboratories, Lundbeck Research USA, Medscape, Merck, Mitsubishi Pharma, MSI Methylation Sciences–Pamlab, Navitor, One Carbon Therapeutics, Otsuka America Pharmaceutical, Pfizer, and Takeda Global Research; he has received royalties from Janssen Research and Development; he has author agreements from Janssen Asia Pacific and Oxford University Press; and he has received grants from the Agency for Healthcare Research and Quality, the Cancer Prevention and Research Institute of Texas, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Center for Advancing Translational Sciences, NIMH, NIDA, Johnson & Johnson, and the Patient-Centered Outcomes Research Institute.
PY - 2018/12
Y1 - 2018/12
UR - http://www.scopus.com/inward/record.url?scp=85057587833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057587833&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2018.18060692
DO - 10.1176/appi.ajp.2018.18060692
M3 - Article
C2 - 30501420
AN - SCOPUS:85057587833
SN - 0002-953X
VL - 175
SP - 1176
EP - 1184
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 12
ER -